Drug class not effective for Alzheimer's

Oct 12, 2006

A study funded by the National Institute of Mental Health in Bethesda, Md., says antipsychotic drugs used to treat Alzheimer's patients are mostly ineffective.

The study, published in the New England Journal of Medicine, concluded that the drugs benefit very few patients with the degenerative illness, and the helpful effects are canceled out by frequent side effects, The Washington Post reported Thursday.

The researchers studied 421 Alzheimer's patients who suffered from disabling agitation, delusions or hallucinations. The patients were randomly assigned a placebo or one of three antipsychotic drugs -- Zyprexa from Eli Lilly; Seroquel from AstraZeneca; and Risperdal from Janssen Pharmaceutical, The New York Times reported.

Lead study author Lon Schneider, a professor of psychiatry, neurology and gerontology at the University of Southern California School of Medicine, said "there were no significant differences between the groups with regard to improvement" after 12 weeks of treatment, the Times said.

Spokesmen for the three pharmaceutical manufacturers said the drugs were not approved by the Food and Drug Administration for Alzheimer's use and the companies did not recommend them for that function.

Copyright 2006 by United Press International

Explore further: FDA warning: men's testosterone drugs overused (Update)

add to favorites email to friend print save as pdf

Related Stories

Research reveals structure of key CRISPR complex

Dec 10, 2014

Using a gene-editing system originally developed to delete specific genes, MIT researchers have now shown that they can reliably turn on any gene of their choosing in living cells.

Recommended for you

FDA warning: men's testosterone drugs overused (Update)

18 hours ago

The Food and Drug Administration is warning doctors against over-prescribing testosterone-boosting drugs for men, saying the popular treatments have not been established as safe or effective for common age-related ...

Early benefit assessment increases transparency for study data

22 hours ago

Four years have passed since the introduction of the German Act on the Reform of the Market for Medicinal Products (AMNOG). AMNOG was primarily aimed at containing the increasing drug expenditure of the statutory health insurance ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.